IL1A and systemic lupus erythematosus: As shown in Figure 1H, the addition of ruxolitinib and/or UCB-Tregs to SLE-PBMCs significantly decreased the soluble form of inflammatory cytokines, including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF (p < 0.0001).